This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Lasmiditan for acute treatment of migraine

< Back

Lasmiditan for acute treatment of migraine


Neurology and Neurosurgery

January 2020

Lasmiditan is a medicinal product currently in clinical development for the acute treatment of migraine. A migraine is usually a moderate or severe headache felt as a throbbing pain on one side of the head. Many people also have symptoms such as nausea, vomiting and increased sensitivity to light or sound. Migraines may be with aura (specific warning signs just before the migraine begins, such as seeing flashing lights), although the most common type is without aura (no specific warning signs).
Lasmiditan presumably exerts its therapeutic action in the treatment of migraine through effects at a specific serotonin receptor called 5-HT1F; however, the precise mechanism is unknown. If licenced, lasmiditan will offer an additional option for first and/or second-line acute treatment of migraine with or without aura in adults.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts